Pharmacoepidemiology (third Edition)

Content: Chapter 1 What is Pharmacoepidemiology? (pages 1–15): Brian L. Strom Chapter 2 Study Designs Available for Pharmacoepidemiology Studies (pages 17–29): Brian L. Strom Chapter 3 Sample Size Considerations for Pharmacoepidemiology Studies (pages 31–39): Brian L. Strom Chapter 4 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies (pages 41–62): Patricia McGettigan, David A. Henry and Sean Hennessy Chapter 5 When Should One Perform Pharmacoepidemiology Studies? (pages 63–71): Brian L. Strom Chapter 6 The Public Health, the University, and Pharmacoepidemiology (pages 73–89): Paul D. Stolley and Joan?Ramon Laporte Chapter 7 A View From Industry (pages 91–108): Dale B. Glasser and Gretchen S. Dieck Chapter 8 A View From Regulatory Agencies (pages 109–124): David J. Graham, Patrick C. Waller and Xavier Kurz Chapter 9 A View From a US Courtroom (pages 125–148): James R. Ruger and Sidney H. Willig Chapter 10 Spontaneous Reporting in the United States (pages 149–174): Dianne L. Kennedy, Stephen A. Goldman and Ralph B. Lillie Chapter 11 Spontaneous Reporting Systems Outside the US (pages 175–192): Bengt?Erik Wiholm, Sten Olsson, Nicholas Moore and Patrick Waller Chapter 12 Intensive Hospital?based Cohort Studies (pages 193–207): Keith Beard and David H. Lawson Chapter 13 Case–Control Surveillance (pages 209–230): Samuel Shapiro Chapter 14 Prescription?event Monitoring (pages 231–246): Ronald D. Mann Chapter 15 Group Health Cooperative of Puget Sound (pages 247–262): Kathleen W. Saunders, Robert L. Davis and Andy Stergachis Chapter 16 Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division (pages 263–283): Gary D. Friedman, Laurel A. Habel, Myde Boles and Bentson H. McFarland Chapter 17 Harvard Pilgrim Health Care/Harvard Vanguard Medical Associates (pages 285–293): K. Arnold Chan and Richard Platt Chapter 18 UnitedHealth Group (pages 295–305): Deborah Shatin, Carole Drinkard and Andy Stergachis Chapter 19 Medicaid Databases (pages 307–324): Jeffrey L. Carson, Wayne A. Ray and Brian L. Strom Chapter 20 Health Databases in Saskatchewan (pages 325–345): Winanne Downey, Patricia Beck, Mary McNutt, Mary Rose Stang, William Osei and Jim Nichol Chapter 21 Automated Pharmacy Record Linkage in The Netherlands (pages 347–360): Hubert G. Leufkens and John Urquhart Chapter 22 The Tayside Medicines Monitoring Unit (MEMO) (pages 361–374): Josie M.M. Evans and Thomas M. Macdonald Chapter 23 The UK General Practice Research Database (pages 375–385): Luis Alberto Garcia Rodriguez, Susanne Perez?Gutthann and Susan Jick Chapter 24 Other Approaches to Pharmacoepidemiology Studies (pages 387–399): Brian L. Strom Chapter 25 How Should One Perform Pharmacoepidemiology Studies? Choosing Among the Available Alternatives (pages 401–413): Brian L. Strom Chapter 26 Bioethical Issues in Pharmacoepidemiology Research (pages 415–431): David Casarett, Jason Karlawish, Elizabeth Andrews and Arthur Caplan Chapter 27 National Medicinal Drug Policies: their Relationship to Pharmacoepidemiology (pages 433–447): Suzanne Hill and David A. Henry Chapter 28 Premarketing Applications of Pharmacoepidemiology (pages 449–462): Harry A. Guess Chapter 29 Studies of Drug Utilization (pages 463–481): David Lee and Ulf Bergman Chapter 30 Evaluating and Improving Physician Prescribing (pages 483–503): Stephen B. Soumerai, Sumit Majumdar and Helene L. Lipton Chapter 31 Drug Utilization Review (pages 505–523): Sean Hennessy, Brian L. Strom, Helene L. Lipton and Stephen B. Soumerai Chapter 32 Determining Causation from Case Reports (pages 525–538): Judith K. Jones Chapter 33 The Use of Randomized Controlled Trials for Pharmacoepidemiology Studies (pages 539–552): Samuel M. Lesko and Allen A. Mitchell Chapter 34 The Use of Pharmacoepidemiology to Study Beneficial Drug Effects (pages 553–572): Brian L. Strom and Kenneth L. Melmon Chapter 35 Pharmacoeconomics: Economic Evaluation of Pharmaceuticals (pages 573–601): Kevin A. Schulman, Henry Glick, Daniel Polsky and John M. Eisenberg Chapter 36 Using Quality of Life Measurements in Pharmacoepidemiology Research (pages 603–613): Gordon H. Guyatt and Roman Jaeschke Chapter 37 N?of?1 Randomized Clinical Trials in Pharmacoepidemiology (pages 615–631): Gordon H. Guyatt, Roman Jaeschke and Robin Roberts Chapter 38 The Use of Meta?analysis in Pharmacoepidemiology (pages 633–659): Jesse A. Berlin Chapter 39 Validity of Pharmacoepidemiology Drug and Diagnosis Data (pages 661–705): Suzanne L. West, Brian L. Strom and Charles Poole Chapter 40 Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety (pages 707–732): Robert T. Chen Chapter 41 Special Methodological Issues in Pharmacoepidemiology Studies of Devices (pages 733–747): Roselie A. Bright Chapter 42 Special Considerations in Studies of Drug?induced Birth Defects (pages 749–763): Allen A. Mitchell Chapter 43 Bias and Confounding in Pharmacoepidemiology (pages 765–784): Jean?Paul Collet and Jean?Francois Boivin Chapter 44 Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis (pages 785–805): Samy Suissa Chapter 45 The Future of Pharmacoepidemiology (pages 807–816): Brian L. Strom This is a thoroughly revised edition of Brian Stroms classic textbook which continues both to reflect the rapid evolution of this new field and to help shape it. Reviews of previous editions of his celebrated textbook include: "The book is essential reading for anyone interested in pharmacoepidemiology." International Journal of Epidemiology "The Second Edition is an excellent textbook and a comprehensive reference which belongs in the library of every pharmaceutical manufacturer and regulator." European Journal of Public Health "Pharmacoepidemiology: Second Edition reflects the maturation of a profession. Strom himself was a major driving force in that maturation " Jacqueline S. Gardner, University of Washington, Seattle, USA While maintaining the popular layout and easy-to-read style that made these earlier editions so successful, this work has been thoroughly revised to reflect the continued development of the field.*Analysis of current issues within the field*Fair representation of issues from around the world*Contains extensive appendices, including a glossary of important terms and sample size tablesThe third edition of Pharmacoepidemiology is an outstanding and fully comprehensive textbook, which will be an essential resource for all interested in the fieldãin academia, in regulatory agencies, in industry and in the law The Third Edition of this successful book has been revised and updated to include the latest advances in the field. It incorporates new topics such as prescription event monitoring, general practice research database, and drug utilization review.Provides an American and European perspective.The authors are renowned in the field